Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.
Regeneus Limited (ASX:RGS) has received a price query from the ASX for a share price gain from $0.091 on 2 March 2016 to a high of $0.155 today, Wednesday, 9 March 2016.
The company said it was not aware of any information concerning it which, could explain the recent trading in securities, and that has not been announced to the market.
The company stated there was recent media coverage of a stem cell trial for knee osteoarthritis carried out in Melbourne showing positive results.
The story was covered initially in Herald Sun news on February 28 and followed with TV coverage on Channel 10 Eyewitness News on February 29.
This news coverage resulted in a high increase of phone enquiries to Regeneus for stem cell therapy for knee osteoarthritis for the days following.
In addition, Regeneus released its half-year financial results with a business update on 29 February, which provided clinical trial updates as well as the company being in advanced discussions with potential Japanese partners for the manufacture, clinical development and commercialization of Progenza in Japan.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.